Table 3.

COVID-19 and IBD in children.

Authors	Patients	Diagnostic Method	Geographic Area	Time/Duration of the Study	Results
Brenner et al., 2021 (pediatric) [32]	IBD and COVID-19: 209	Laboratory diagnosis	23 countries (SECURE-IBD and COVID-19 Pediatric IBD Porto Group)	Until 01 October 2020	7% hospitalizations, of which 1% mechanical ventilation (sulfasalazine/mesalazine therapy, they developed multisystemic inflammation and superinfection). 0 deaths Hospitalization rate < IBD adult patients (33–66%)
Turner et al., 2020 (pediatric) [33]	PIBD: 102 COVID-19: 8 (6 confirmed)	Laboratory diagnosis in 6 patients Highly suspected clinic in 2 patients	Porto Group-affiliated Pediatric IBD centers in Europe	Until 26 March 2020	Only mild symptoms (fever, cough, ageusia, myalgia, anosmia, asthenia)
		Laboratory diagnosis or clinic suspect	China	Until 20 March 2020	Out of 917 pediatric cases of SARS-CoV-2 infection, none had IBD
Sansotta et al., 2021 (pediatric) [34]	PIBD: 290 COVID-19: 24 (8%)	Clinic in 22 patients Molecular swab in 2 patients	Lombardy (Italy)	21 February 2020–04 May 2020 (lockdown period)	Only 8% of children developed COVID-like symptoms, on which the supposed diagnosis was based given the scarce availability of swabs. 42% thiopurine therapy, 30% salicylates, 16% organic. No severe course or need for hospitalization

IBD: inflammatory bowel disease. PIBD: pediatric inflammatory bowel disease. PCR: polymerase chain reaction.